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Abstract
Autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and 
systemic sclerosis (scleroderma) preferentially affect women, and are characterized by systemic 
inflammation leading to target organ dysfunction. The public health burden of autoimmune 
diseases, which collectively represent a leading cause of morbidity and mortality among women 
throughout adulthood, is substantial. While some features of these diseases have been observed to 
improve over the menopausal transition, such as disease flare rate in SLE and skin softening and 
thinning in scleroderma, others, such as swollen and tender joints and radiographically confirmed 
damage in RA may worsen. The general trends, however, are not consistent or conclusive for all 
disease-related manifestations. Of great importance is the recognition that comorbid diseases, 
including osteoporosis and accelerated cardiovascular disease, contribute excess morbidity and 
mortality that becomes increasingly apparent as women with autoimmune diseases undergo the 
menopausal transition.
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Background
Autoimmune diseases are characterized by systemic inflammation, in which a dysregulated 
immune system causes damage or dysfunction to target organs. Rheumatic autoimmune 
diseases include conditions such as systemic lupus erythematosus (SLE), rheumatoid 
arthritis (RA) and systemic sclerosis (scleroderma), in which the connective tissues 
(cartilage, joint synovium, skin) are most frequently targeted. Collectively, the autoimmune 
diseases are estimated to afflict over 7 % of the general population [1]; RA is among the 
most common autoimmune diseases, with RA prevalence of greater than 1 % of the adult 
female population in the United States [2]. While rheumatic autoimmune diseases can occur 
across the lifespan, the typical presentation occurs in mid- or late- adulthood [3]. These 
diseases are considerably more common in women than in men, with approximately 90 % of 
prevalent cases being female for SLE and scleroderma, and approximately 75 % for RA [3]. 
Effective targeted therapies for RA have rapidly expanded over the last decade, leading to 
improved outcomes, but treatment options for SLE and scleroderma remain largely based on 
traditional immunosuppressive and anti-inflammatory agents which are associated with a 
range of toxicities [4]. Major comorbidities for the rheumatic autoimmune diseases include 
premature cardiovascular disease and osteoporosis, due both to underlying disease and 
chronic exposure to glucocorticoids [5–7]. Data from the last 15 years have demonstrated 
that when autoimmune diseases are considered as a group, they rank among the 10 leading 
causes of death among women under age 75 years [8, 9].
While varying effects of estrogen and other sex hormones have been proposed related to the 
predisposition and development of autoimmune diseases and their comorbidities, the roles of 
genetics, environmental factors, and their interactions undoubtedly play significant roles 
[10]. This review will discuss the epidemiology and clinical features of three systemic 
rheumatic autoimmune diseases—SLE, RA and scleroderma—in relation to women in 
midlife.
Review
This review is aimed at providing an overview of key topics related to women’s midlife 
health that are thought to have distinct features and implications for women with 
autoimmune diseases compared to the general population. While not intended to serve as an 
exhaustive review of the literature, the authors screened and reviewed studies predominantly 
from the last two decades related to epidemiologic patterns and clinical features of SLE, RA 
and scleroderma in relation to midlife, with emphasis on large, population-based studies 
when available, in order to synthesize recurrent themes.
Epidemiologic overview
It is well-recognized that the majority of autoimmune diseases disproportionately afflict 
females. This is true for the rheumatic autoimmune diseases, with few exceptions, such as 
granulomatosis with polyangiitis (formerly termed Wegener’s granulomatosis) and 
vasculitis, which have sex ratios closer to 1:1 [3]. However, for the female-predominant 
diseases, the magnitude of female preponderance tends to wane in older age groups. In terms 
of lifestage of greatest risk, a long-held perception has been that SLE and other rheumatic 
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disease are most likely to occur in women during their reproductive years. Recent 
epidemiologic data have provided the basis for a more nuanced view related to sex-specific 
patterns of disease, with SLE perhaps serving as the clearest example. A study of SLE 
incidence during the 1990s in the United Kingdom including 1638 incident cases revealed 
that among females in this population of predominantly European ancestry, risk of SLE rose 
steadily with age among females until 50–54 years of age, and thereafter steadily declined; 
in males, incidence increased steadily until 70–74 years of age before declining [11]. This 
data-driven observation of peak incidence in females occurring around the time of 
menopause was a novel finding, and contrasted with the premise of SLE as a “disease of 
women of childbearing age.” More recently, lupus registries from sociodemographically 
diverse populations in the United States have provided evidence for disparities in the risk of 
disease in different population subsets [12]. Data from the Michigan Lupus Epidemiology & 
Surveillance (MILES) Program [13] demonstrate a clear peak in incidence among black 
females during the 25–29 year age range; the magnitude and young age of peak incidence in 
this group are striking in comparison to other groups (Fig. 1). White females in the Michigan 
population experienced highest incidence between the ages of 30 and 34, but their peak was 
much less distinct and tapered slowly throughout the midlife years. With the younger risk of 
developing disease among black females, the highest prevalence occurred in midlife, at 40–
44 years of age. MILES Registry data has also documented a higher SLE incidence and 
younger age of diagnosis in the Arab/Chaldean American population compared to non-Arab/
Chaldean American whites, with prevalence among the Arab/Chaldean American population 
peaking in the 30–39 year age group [14].
Another registry in the United States, focused on the American Indian/Alaska Native 
population, found high rates of lupus, with incidence among American Indian/Alaska Native 
females similar to that of black females, and prevalence approximately 1.5 times higher [15]. 
Peak incidence in the American Indian/Alaska Native population (for females and males 
combined) occurred in the 40–49 year age span [15]. Together, contemporary SLE 
epidemiology data underscore varying patterns of risk in different population subsets, but 
clearly a high burden of disease among women in midlife.
Primary ovarian insufficiency among women with rheumatic autoimmune diseases
When considering the subject of menopausal timing and its effects among populations of 
women with rheumatic autoimmune diseases, the possibility of exposure to gonadotoxic 
therapies used to treat severe manifestations of these conditions must be considered [16]. 
Potent first line immunosuppressive therapy for target-organ threatening manifestations of 
autoimmune diseases (e.g., lupus nephritis, systemic vasculitis, scleroderma) has historically 
been the combination of high dose corticosteroids and a gonadotoxic alkylating agent 
including cyclophosphamide, chlorambucil and even nitrogen mustard. Many women who 
received and continue to receive cyclophosphamide for rheumatic diseases, as well as for 
hematologic and solid organ malignancies, experience irreversible gonadal toxicity as a 
result of this therapy, leading to primary ovarian insufficiency [17–20]. Primary ovarian 
insufficiency, also known as premature ovarian failure, is defined as menopause before the 
age of 40 years [21]. Unlike with natural menopause, which occurs on average around age 
50 years, 50 % of women with primary ovarian insufficiency still have variations in ovarian 
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function and 5–10 % conceive following this diagnosis [22, 23]. There is lack of evidence 
that assisted reproductive technologies have efficacy in this population [23].
A major focus over the past two decades has been the development of alternate therapeutic 
regimens that minimize cyclophosphamide exposure in this patient population, as well as the 
use of adjuvant therapy such as with gonadotropin-releasing hormone analogues (e.g., 
leuprolide acetate), to preserve ovarian function during cyclophosphamide therapy [24]. 
Practice has evolved in recent years towards increased utilization of less toxic 
immunosuppressive therapies such as rituximab and mycophenolate mofetil in vasculitis and 
lupus nephritis respectively, as well as the adoption of lower-dose cyclophosphamide 
regimens (e.g., “Euro-Lupus” [25, 26]) for treating many cases of lupus nephritis. In 
addition to the increase in widespread off-label use of gonadotropin-releasing hormone 
analogues during cyclophosphamide therapy, these changes in standard of care therapy are 
allowing for rheumatic disease patients to achieve natural menopause at a rate that may soon 
mirror that of the general public.
Systemic lupus erythematosus
SLE is a chronic, systemic inflammatory disease with a waxing and waning course, that can 
affect multiple organs, with the kidneys, joints, and skin most commonly involved. 
Symptoms can range from mild, including photosensitive rashes, mucosal ulcerations, and 
pleurisy, to severe and even life threatening, with rapidly progressive glomerular nephritis, 
central nervous system inflammation or hemolytic anemia. Lupus is classically considered 
an autoantibody-mediated disease, with evidence of immune complex deposition seen in 
renal and dermal biopsies of patients with active disease. Lupus patients also have 
heightened risk of cardiovascular disease that is not explained by traditional Framingham 
risk factors [27, 28], due at least in part to disease associated endothelial dysfunction that 
contributes to the accelerated atherosclerotic disease that also characterizes SLE [29–31]. 
Long-term studies of lupus outcomes have therefore included several means of quantifying 
disease. For example, the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 
[32] is a widely used tool that measures recent disease activity, incorporating clinical history, 
physical exam and laboratory findings. The “SLICC/ACR” Damage Index [33] is used in 
lupus patients to quantify cumulative damage in 12 different target organs over time 
regardless of etiology; notably, it captures disease burden induced by cardiovascular disease, 
osteoporosis due to prolonged corticosteroid use and chronic inflammation, and the additive 
sequelae of premature menopause due to gonadotoxic therapy.
As stated previously, SLE incidence for women of predominantly European ancestry has 
been observed to rise steadily with age until the 50s, and decline thereafter. Multiple 
population based studies support the observation that the clinical course and disease 
manifestations of SLE are different if the disease onset occurs after natural menopause. 
Some studies have described a milder course associated with later disease onset, with 
general observations of less renal and mucocutaneous involvement, but higher rates of 
interstitial lung disease, neurologic complications and sicca symptoms [34–38]. Other 
studies have noted no difference in the clinical course of SLE between these two populations 
[39, 40]. However, data from a longitudinal and multiethnic cohort of 73 women with late-
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onset SLE (onset at age ≥ 50 years) and 144 matched women with earlier onset SLE found 
late-onset SLE to be independently associated with both damage (measured by the “SLICC/
ACR” Damage Index [33]; OR 23.3, 95 % CI 4.0–141.6) and mortality (OR 10.7, 95 % CI 
3.1–37.6) [37]. Thus, while in general it seems that most studies support a more mild course 
of lupus activity in later onset disease, the accrual of lupus damage as reflected in part by 
comorbid disease is probably greater in this group [41].
Varying degrees of improvement in lupus disease activity have been observed after women 
go through hormone withdrawal, whether due to natural menopause, hysterectomy or 
primary ovarian insufficiency after cyclophosphamide [41–44]. Although heterogeneous and 
somewhat difficult to compare given differences in age of the study populations and duration 
of follow-up, in general the research supports a trend toward fewer lupus disease flares after 
hormone withdrawal, but significantly more damage accrual.
Rheumatoid arthritis
RA is a systemic disease that can lead to erosive, destructive joint damage, as well as “extra-
articular” disease involving not just the joints, but target organ tissues of the body including 
the lungs, blood vessels, eyes and nervous system. This is particularly true for those people 
who are “seropositive” for the characteristic autoantibodies of rheumatoid factor and anti-
cyclic citrullinated peptide antibodies. As mentioned above, RA is also associated with 
excess mortality compared with the general population, which is predominantly due to 
accelerated atherosclerotic cardiovascular disease [45–47]. As is true with antinuclear 
antibody positive diseases, RA preferentially affects women, in ratios around 4:1 [48], and 
has a peak incidence in females following menopause (age 55–64 years), a full two decades 
prior to age of peak incidence in men (75–84 years) [48]. Interestingly, the female-to-male 
incidence ratio after age 60 years is approximately 1:1, potentially implicating changes in 
sex hormones in the development of RA [49]. A disease with waxing and waning activity, 
RA is clearly influenced by sex hormones throughout adult life: multiple population-based 
studies have found that women with RA have a lower mean age at menopause compared to 
controls [50–52] and a pattern of RA symptom improvement or even remission during 
pregnancy is well recognized [50].
What is less well understood, however, is the role of gonadal hormones in both the risk for 
developing the disease, as well as the timing and severity of its manifestations. 
Observational studies that have assessed menopause by patient self-report, with variable 
lengths of recall, do not uniformly specify surgical or non-surgical menopause among their 
study populations, and have produced conflicting results. For example, a prospective cohort 
study of 31,336 women in Iowa, aged 55 to 69 years at cohort baseline and followed for 11 
years, revealed 158 incident cases of RA, with age at last pregnancy and age at menopause 
each significantly inversely associated with RA [53]. In this study, no effect was found 
related to onset of menarche, oral contraceptive use or hysterectomy/oophorectomy, though 
those women who underwent later menopause (after age 51 years) were at decreased risk of 
developing RA compared to those who underwent menopause at or below age 45. However, 
a recent study, in which a group of 534 patients in a Canadian inception cohort of RA 
patients were divided into an “early menopause” (mean age 38.5 years) and “usual 
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menopause” group (mean age 51.7 years), the age of RA disease onset was found to be 
similar between the groups [54]. Furthermore, the early menopause patients were more 
likely to be rheumatoid factor positive, a characteristic of the disease that is known to impart 
increased risk of erosive joint disease as well as extra-articular, systemic manifestations 
(e.g., vasculitis, interstitial lung disease). This study did include persons who underwent 
surgical menopause. In contrast, a subsequent study of 134 women with RA and earlier 
menopause (age <45 years) revealed that these women had more mild-moderate disease, and 
more rheumatoid factor negative disease, than women who underwent later menopause [52]; 
it is unclear if women who underwent surgical menopause were excluded from the earlier 
menopause group. It is therefore difficult to interpret these results other than to restate the 
observation that, like other autoimmune diseases, the role of sex hormones is significant but 
complex, and clearly not fully elucidated. However, general observations about the impact of 
menopause in this patient population are not in dispute. The heightened risk of accelerated 
cardiovascular disease [55], excessive bone density loss due to long-term corticosteroid 
therapy, and the possibility of primary ovarian insufficiency due to previous exposure to 
gonadotoxic therapies, in the context of ongoing underlying systemic inflammatory diseases, 
all confound the care and management of these patients as they age, and should prompt 
vigilance on the part of caregivers to address any modifiable risk factors associated with 
these conditions.
RA disease activity is typically measured using the 28-joint count disease activity scale 
(DAS-28) [56], an assessment of progression of bone X-ray changes, and patient-reported 
health assessment questionnaires. The largest study to address the effect of menopausal 
transition on RA was conducted in a cohort of early RA patients using these measures. Post-
menopausal women in this cohort (n = 109) were found to have more significant joint 
damage on X-ray, in addition to higher scores on the DAS-28 and health assessment scores 
both at baseline and at 6-year follow-up, when compared to pre-menopausal women (n = 64) 
and age-matched men (n = 85) [51]. The menopausal state in this study was thought to be a 
primary factor underlying the differences observed between these groups of RA patients.
Systemic sclerosis (or scleroderma)
Scleroderma is an inflammatory disease that causes vasculopathy and fibrosis and scarring 
in multiple target organs, including the vasculature, lungs, gastrointestinal tract and skin. 
Skin thickening is a defining feature of scleroderma, which is characterized by excessive 
production of extracellular matrix proteins (e.g., collagen, laminin, fibronectin) by skin 
fibroblasts [57]. The peak incidence of scleroderma is in the fifth and sixth decades, and 
scleroderma predominantly affects women (with a female-to-male ratios ranging from 3:1 to 
14:1) [58].
In the general population, menopause is characterized by a low estrogenic state and is 
associated with skin thinning due to decreased extracellular matrix protein deposition by 
fibroblasts [59]. Although thinning of the dermis often accompanies aging, most studies 
suggest that collagen loss is more closely related to postmenopausal status than chronologic 
age, reflecting hormonal changes [60]. Investigators have observed a mean decline in dermal 
collagen of approximately 1–2 % per year after menopause [61]. Estrogen supplementation 
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in postmenopausal women has been reported to improve skin thickness by increasing skin 
collagen content [62].
Although scleroderma most commonly occurs near the end of the reproductive period and 
predominantly affects women, there has been only one study investigating the impact of 
menopause on skin thickening in women with scleroderma [58]. Investigators, using 
previously collected data from 1070 women with scleroderma enrolled within the Canadian 
Scleroderma Research Group (CSRG) cohort, found that postmenopausal status in women 
with diffuse scleroderma was associated with a substantially lower mean modified Rodnan 
Skin Score, a validated measure of skin thickening, compared to premenopausal status 
(effect estimate of −2.62 units, 95 % CI −4.44, −0.80) [58]. This effect was independent of 
age, follow-up time, and disease duration. However, postmenopausal status had a smaller 
effect on skin thickening in women with limited scleroderma compared to women with 
diffuse scleroderma (effect estimate of −0.58 units, 95 % CI −1.50, 0.34).
The findings from this study are supported by previous experimental evidence showing that 
estrogen increases extracellular matrix protein production in skin fibroblast cultures of 
scleroderma patients [62]. In addition, an estrogen-receptor inhibitor (i.e., tamoxifen) 
induced a significant decrease of these extracellular matrix proteins in cultures of 
scleroderma skin fibroblasts [62]. Moreover, it is well-established that estrogen stimulates 
normal skin fibroblasts to produce transforming growth factor-beta 1, as well as monocytes 
and macrophages to produce platelet-derived growth factor, which are both key profibrotic 
cytokines in scleroderma skin disease [57, 63]. As scleroderma skin fibroblasts show 
increased expression of transforming growth factor-beta 1 receptor and platelet-derived 
growth factor receptor, the study investigators postulated that estrogen might play a role in 
scleroderma pathogenesis through its stimulatory effect on these two cytokines [58].
Furthermore, early menopause in women with scleroderma may contribute adverse lowering 
of bone mineral density in affected women, though the competing effects of underlying 
systemic inflammation and long term treatment with corticosteroids make it difficult to 
assess the relative impact of early menopause. Several studies have shown a potentially 
reduced bone mineral density in women with scleroderma compared to control women. A 
recent systematic literature review summarized data about the prevalence of low bone 
mineral density and its risk factors in scleroderma [64]. The search resulted in ten studies, 
which reported a lower bone mineral density in patients with scleroderma compared to 
matched controls, while two studies reported no difference. Potential risk factors for low 
bone mineral density in women with scleroderma included early age at menopause, as well 
as traditional risks factors such as family history of osteoporosis, age, low vitamin D levels, 
in addition to disease-related factors such as diffuse disease subtype, presence of internal 
organ involvement, and calcinosis. However, early menopause was inconsistently assessed 
across included studies, which makes it difficult to draw firm conclusions about the 
significance and size of its effect on bone mineral density in scleroderma women [64].
As mentioned previously, vasculopathy is an important disease-related manifestation in 
scleroderma. Since estrogen has well-established beneficial effects on the vascular system, 
the low estrogenic state associated with menopause has been suggested to aggravate vascular 
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manifestations in scleroderma women [65]. In a retrospective cohort study of 189 
scleroderma women with neither pulmonary arterial hypertension nor interstitial lung 
disease at baseline, investigators assessed the effect of postmenopausal status on the risk of 
isolated pulmonary arterial hypertension. During a mean follow-up of 15.9 years [standard 
deviation (SD) 11.3], 63 (33 %) women developed isolated pulmonary arterial hypertension. 
Postmenopausal status was significantly associated with more than a 5-fold increase in the 
risk of isolated pulmonary arterial hypertension, accounting for disease and human 
leukocyte antigen (HLA) subtypes [66]. Furthermore, another retrospective cohort study 
from the same group evaluated the effect of hormone replacement therapy on the risk of 
isolated pulmonary arterial hypertension in females with scleroderma [67]. Sixty-one 
postmenopausal women with limited scleroderma and without evidence of isolated 
pulmonary arterial hypertension or interstitial lung disease at cohort entry were studied. 
Among these, 23 were treated with hormone replacement therapy for a mean of 6.7 years 
(SD 3.7), of whom none developed isolated pulmonary arterial hypertension during follow-
up. However, among the 41 women unexposed to hormone replacement therapy, 8 (20 %) 
developed isolated pulmonary arterial hypertension over a similar period of follow-up. This 
difference was not accounted for by age, autoantibody profile, lung diffusing capacity at 
menopause onset, or calcium channel blocker use. The investigators concluded that hormone 
replacement therapy might prevent the onset of isolated pulmonary arterial hypertension in 
patients with limited scleroderma.
Observational studies have also reported a higher prevalence of atherosclerotic 
cardiovascular disease in scleroderma patients in comparison to healthy individuals, with its 
presence being associated with poorer prognosis [68]. The mechanisms leading to increased 
atherosclerosis in scleroderma are not completely understood, but some have proposed 
endothelial dysfunction due to inflammation and vasculopathy, which might potentially 
interact with traditional risk factors, including age and menopause, as important contributing 
factors [68].
Although the menopause-related decline in estrogen appears to have a beneficial effect on 
skin thickening in scleroderma, it might have an adverse effect on the pulmonary arterial 
vasculature as well as atherosclerotic cardiovascular disease in affected women. 
Observational studies of menopause in women with scleroderma highlight the pleiotropic 
role that estrogen might play in scleroderma pathophysiology and prompt further research to 
better understand its complexity.
Conclusions
It is difficult to disentangle the true impact of reproductive aging on the natural history of 
rheumatic autoimmune diseases. However, what seems clear is that the effects of major 
comorbidities associated with aging, which are likely accelerated in rheumatic autoimmune 
diseases, are magnified as these women approach midlife and beyond. This is due in part to 
the compounding effects of the underlying diseases and their treatments, such as long-term 
corticosteroid use and gonadotoxic immunosuppression, in addition to recognized vascular 
endothelial dysfunction that exists across the spectrum of these diseases. The public health 
burden of autoimmune diseases, which collectively represent a leading cause of morbidity 
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and mortality among women throughout adulthood, is substantial. Their impact on women’s 
health becomes even more complex through menopause. With greater numbers of these 
patients achieving longer lives due to therapeutic advances, ascertaining the true impact of 
menopause on rheumatic autoimmune disease should be considered a priority for women’s 
health.
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Fig. 1. 
SLE incidence data from the Michigan Lupus Epidemiology & Surveillance (MILES) 
Program Registry [13]. SLE was defined according to the American College of 
Rheumatology (ACR) classification criteria for SLE [69, 70]
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